MRK | Weekly | Haru Insights

Merck’s personalized mRNA cancer vaccine intismeran (V940/mRNA-4157) achieved pivotal Phase III success, delivering transformative clinical data that confirmed its potential as a paradigm-shifting therapy for high-risk melanoma when combined with Keytruda—marking a major milestone in immuno-oncology.
Merck completed its $600 million acquisition of Mirus Bio LLC, a strategic move to strengthen its viral vector manufacturing capabilities and cement its leadership in the rapidly growing cell and gene therapy space—critical for advancing next-generation precision medicine.

Merck is no longer just a Keytruda story—it’s redefining immuno-oncology with a next-gen pipeline anchored in high-conviction assets like the TWINPEAK trial, proving its ability to innovate beyond blockbuster drugs and build a sustainable legacy in precision medicine.
The market’s growing recognition of Merck as a defensive quality-growth stock, highlighted by Goldman Sachs’ endorsement and ultra-low Zacks Rank sentiment, reflects deep institutional confidence in its scientific leadership and long-term strategic vision.
The successful Phase III data for intismeran validates Merck’s bold bet on mRNA in oncology, turning a high-risk platform into a clinically proven, potentially transformative therapeutic approach with broad applicability across multiple cancers.
The Mirus Bio acquisition is a masterstroke—securing end-to-end viral vector capacity at scale, which removes a critical bottleneck in gene therapy development and positions Merck as a dominant player in the future of curative medicine.
With analysts increasingly focused on Merck’s pipeline resilience and innovation momentum, the company is shifting from a revenue-dependent model to one driven by scientific breakthroughs with global commercial potential, reinforcing its premium valuation.

Merck & Co., Inc. (MRK)[Tv]